Sarah Singleton completed her Bachelors of Science in Biochemistry at Simmons University in Boston, Massachusetts (2018-2021). Then, completed the Research Scholar Initiative at the Harvard University Graduate School of Arts and Sciences, with research and mentorship from the Novartis Institutes of Biomedical Research. There, she worked to elucidate novel immunological targets to shape the tumor microenvironment (2021-2022) and on novel biological small molecule drug development (2022-2023). In the Conway Group, she focuses on the development of mutant zinc fingers as drug targets, applied to medically and biologically-relevant proteins.